Download PDF
Dtsch Med Wochenschr 2010; 135(47): 2370
DOI: 10.1055/s-0030-1269402
Pro & Contra | Commentary
Intensivmedizin
© Georg Thieme Verlag KG Stuttgart · New York

Aktiviertes Protein C im septischen Schock – pro

Activated protein C in patients with septic shock: proG. Marx1
  • 1Klinik für Operative Intensivmedizin, Universitätsklinikum Aachen
Further Information

Publication History

Publication Date:
16 November 2010 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

aktiviertes Protein C - Drotrecogin alfa - Sepsis - septischer Schock

Keywords

aktivated protein C - drotrecogin alfa - sepsis - septic shock

Literatur

  • 1 Angus D C. et al . The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.  Crit Care Med. 2004;  32 2199-2206
    Google Scholar
  • 2 Bernard G R. et al . Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 699-709
    Google Scholar
  • 3 Eichacker P Q. et al . Reassessing recombinant human activated protein C for sepsis.  Crit Care Med. 2005;  33 2426-8
    Google Scholar
  • 4 Levy M M. et al . The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis.  Intensive Care Med. 2010;  36 222-231
    Google Scholar
  • 5 Vincent J L. et al . Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE.  Crit Care Med. 2005;  33 2266-2267
    Google Scholar

Prof. Dr. Gernot Marx

Klinik für Operative Intensivmedizin
Universitätsklinikum der RWTH Aachen

Pauwelsstr. 30

52074 Aachen

Phone: 0241/80-80444

Fax: 0241/80-3380444

Email: gmarx@ukaachen.de

URL: http://www.operative-intensivmedizin.de

      >